71 results
Page 2 of 4
424B5
b33eds
21 Dec 20
Prospectus supplement for primary offering
12:00am
424B5
egfl37o9zrorot
17 Dec 20
Prospectus supplement for primary offering
5:13pm
8-K
EX-1.1
fy80q
5 Aug 20
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
9:56pm
8-K
EX-10.1
70spd2
26 Jun 20
Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets
5:27pm
424B3
kdp5zgpul66vt95evt53
15 May 20
Prospectus supplement
4:34pm
424B3
1bu8hkplj7
15 Apr 20
Prospectus supplement
4:27pm
8-K
EX-10.1
ovb djj32ce3d5erd4i7
26 Mar 20
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
7:05am
8-K
EX-10.1
hg8u 3t3q
27 Jan 20
Entry into a Material Definitive Agreement
12:00am
CORRESP
yso 8tw2cnslk35cut
3 Oct 19
Correspondence with SEC
12:00am
8-K
EX-1.1
117vbzy5lnsu5js2
4 Mar 19
Entry into a Material Definitive Agreement
4:15pm